-
Something wrong with this record ?
Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis
M. Blaha, M. Lanska, V. Blaha, L. Boudys, P. Zak,
Language English Country Netherlands
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT14265
MZ0
CEP Register
NT14037
MZ0
CEP Register
- MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Phenotype MeSH
- Genetic Predisposition to Disease MeSH
- Homozygote * MeSH
- Hyperlipoproteinemia Type II blood diagnosis genetics therapy MeSH
- Immunosorbent Techniques * MeSH
- Pregnancy Complications blood diagnosis genetics therapy MeSH
- Cholesterol, LDL blood MeSH
- Receptors, LDL genetics MeSH
- Humans MeSH
- Mutation * MeSH
- DNA Mutational Analysis MeSH
- Live Birth MeSH
- Blood Component Removal methods MeSH
- Severity of Illness Index MeSH
- Pregnancy MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
INTRODUCTION: Rare cases of pregnancy in women with homozygous familial hypercholesterolemia (HFH) have been reported. HFH might pose significant risks for the mother and her fetus. Statins, the most potent agents for low-density lipoprotein (LDL) cholesterol reduction, are contraindicated; thus lipoprotein apheresis remains the only effective treatment. CASE REPORT: We report on a 34-year-old pregnant woman with HFH who was treated throughout the entire pregnancy by lipoprotein apheresis (immunoadsorption method). Increasing levels of LDL-cholesterol were stabilized at 9-10 mmol/L by lipoprotein apheresis (performed every 10 days). No complications were observed during the treatment procedures. Monitoring of the fetus revealed no impairment of the umbilical cord and blood flow in the uterine arteries, as well as no intrauterine growth retardation. The delivery was spontaneous and the child was breastfed for two months. CONCLUSION: Intensive treatment by lipoprotein apheresis is an effective and safe therapeutic strategy during pregnancy, even in severe cases of HFH, as it can stabilize progressively increasing lipoprotein levels and prevent severe complications.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010240
- 003
- CZ-PrNML
- 005
- 20191114120421.0
- 007
- ta
- 008
- 160408s2015 ne f 000 0|engg|
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosissup.2015.02.024 $2 doi
- 024 7_
- $a 10.1016/j.atherosclerosissup.2015.02.024 $2 doi
- 035 __
- $a (PubMed)25936317
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bláha, Milan, $u 4th Department of Internal Medicine - Haematology, Charles University, Faculty of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. $d 1938- $7 xx0034440
- 245 10
- $a Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis / $c M. Blaha, M. Lanska, V. Blaha, L. Boudys, P. Zak,
- 520 9_
- $a INTRODUCTION: Rare cases of pregnancy in women with homozygous familial hypercholesterolemia (HFH) have been reported. HFH might pose significant risks for the mother and her fetus. Statins, the most potent agents for low-density lipoprotein (LDL) cholesterol reduction, are contraindicated; thus lipoprotein apheresis remains the only effective treatment. CASE REPORT: We report on a 34-year-old pregnant woman with HFH who was treated throughout the entire pregnancy by lipoprotein apheresis (immunoadsorption method). Increasing levels of LDL-cholesterol were stabilized at 9-10 mmol/L by lipoprotein apheresis (performed every 10 days). No complications were observed during the treatment procedures. Monitoring of the fetus revealed no impairment of the umbilical cord and blood flow in the uterine arteries, as well as no intrauterine growth retardation. The delivery was spontaneous and the child was breastfed for two months. CONCLUSION: Intensive treatment by lipoprotein apheresis is an effective and safe therapeutic strategy during pregnancy, even in severe cases of HFH, as it can stabilize progressively increasing lipoprotein levels and prevent severe complications.
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a separace krevních složek $x metody $7 D001781
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a mutační analýza DNA $7 D004252
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 12
- $a homozygot $7 D006720
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipoproteinemie typ II $x krev $x diagnóza $x genetika $x terapie $7 D006938
- 650 12
- $a imunosorpční techniky $7 D007163
- 650 _2
- $a narození živého dítěte $7 D050498
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a komplikace těhotenství $x krev $x diagnóza $x genetika $x terapie $7 D011248
- 650 _2
- $a LDL-receptory $x genetika $7 D011973
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lánská, Miriam $u 4th Department of Internal Medicine - Haematology, Charles University, Faculty of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. $7 jx20100315020
- 700 1_
- $a Bláha, Vladimír, $u 3rd Department of Medicine - Metabolic Care and Gerontology, Charles University, Faculty of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. $d 1964- $7 xx0002944
- 700 1_
- $a Boudyš, Luděk $u Department of Obstetrics and Gynecology, Charles University, Faculty of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. $7 xx0195636
- 700 1_
- $a Žák, Pavel, $u 4th Department of Internal Medicine - Haematology, Charles University, Faculty of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. Electronic address: pavel.zak@fnhk.cz. $d 1966- $7 mzk2006354145
- 773 0_
- $w MED00006853 $t Atherosclerosis. Supplements $x 1878-5050 $g Roč. 18, č. - (2015), s. 134-139
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25936317 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20191114120659 $b ABA008
- 999 __
- $a ok $b bmc $g 1113669 $s 934608
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 18 $c - $d 134-139 $i 1878-5050 $m Atherosclerosis supplements $n Atheroscler Suppl $x MED00006853
- GRA __
- $a NT14265 $p MZ0
- GRA __
- $a NT14037 $p MZ0
- LZP __
- $a Pubmed-20160408